Phase I/II Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas (Primary Effusion Lymphoma and Large Cell Lymphoma Arising in KSHV-Associated Multicentric Castleman Disease)

Trial Profile

Phase I/II Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas (Primary Effusion Lymphoma and Large Cell Lymphoma Arising in KSHV-Associated Multicentric Castleman Disease)

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 22 May 2017

At a glance

  • Drugs Pomalidomide (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Rituximab; Vincristine
  • Indications Giant lymph node hyperplasia; Kaposi's sarcoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 06 May 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 04 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top